9205 W. Russell Road
Suite 240
Las Vegas, NV 89148
United States
866-721-0297
https://www.gbsciences.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 3
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. John Claybron Poss | CEO, Interim CFO & Chairman | 60k | S.O. | 1948 |
Dr. Andrea Small-Howard M.B.A., MBA, Ph.D. | Chairman of Scientific Advisory Board, Chief Science Officer, President & Director | 138k | S.O. | 1969 |
Mr. Gary R. Henrie Esq. | Securities Counsel & Company Secretary | S.O. | S.O. | 1954 |
GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. was incorporated in 2001 and is based in Las Vegas, Nevada.
L’ISS Governance QualityScore de GB Sciences, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..